Free Trial
NASDAQ:ELEV

Elevation Oncology (ELEV) Stock Price, News & Analysis

Elevation Oncology logo
$0.58 -0.05 (-7.30%)
(As of 12/20/2024 05:45 PM ET)

About Elevation Oncology Stock (NASDAQ:ELEV)

Key Stats

Today's Range
$0.55
$0.66
50-Day Range
$0.52
$0.75
52-Week Range
$0.44
$5.83
Volume
2.48 million shs
Average Volume
1.48 million shs
Market Capitalization
$34.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.20
Consensus Rating
Buy

Company Overview

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Elevation Oncology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

ELEV MarketRank™: 

Elevation Oncology scored higher than 40% of companies evaluated by MarketBeat, and ranked 707th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elevation Oncology has only been the subject of 3 research reports in the past 90 days.

  • Read more about Elevation Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Elevation Oncology are expected to decrease in the coming year, from ($0.85) to ($0.91) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevation Oncology is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevation Oncology is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elevation Oncology has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.78% of the float of Elevation Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevation Oncology has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Elevation Oncology has recently increased by 1.83%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Elevation Oncology does not currently pay a dividend.

  • Dividend Growth

    Elevation Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.78% of the float of Elevation Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevation Oncology has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Elevation Oncology has recently increased by 1.83%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Elevation Oncology has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Elevation Oncology this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for ELEV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevation Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Elevation Oncology is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Elevation Oncology's insider trading history.
Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Stock News Headlines

Elevation Oncology's (ELEV) Buy Rating Reaffirmed at HC Wainwright
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Elevation Oncology enters licensing agreement with Synaffix B.V.
See More Headlines

ELEV Stock Analysis - Frequently Asked Questions

Elevation Oncology's stock was trading at $0.5370 at the start of the year. Since then, ELEV stock has increased by 8.0% and is now trading at $0.58.
View the best growth stocks for 2024 here
.

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.02.

Elevation Oncology (ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

Elevation Oncology's top institutional shareholders include Frazier Life Sciences Management L.P. (10.14%), Geode Capital Management LLC (1.88%), Sphera Funds Management LTD. (1.83%) and State Street Corp (1.72%).
View institutional ownership trends
.

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/06/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELEV
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.20
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,141.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-45,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.29 per share

Miscellaneous

Free Float
54,330,000
Market Cap
$34.29 million
Optionable
Optionable
Beta
1.24
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ELEV) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners